期刊文献+

以发热、胸水为首发症状的慢性粒细胞白血病1例 被引量:1

One case of chronic myelogenous leukemia with fever and hydrothorax as initial symptom
下载PDF
导出
摘要 回顾分析1例以发热、胸水为首发症状的慢性粒细胞白血病的临床病理特征。胸水涂片结合细胞块免疫组化考虑髓系肿瘤。基因检测:BCR-ABL1融合基因ABL1激酶区发生E279K突变。骨髓检查:CML(急变期)。胸水中能够及时发现白血病细胞对于临床判断疾病的进展和调整治疗方案有重要价值。 A case of chronic myeloid leukemia with fever and hydrothorax as the first symptom is to be retrospectively analyzed. M yeloid tumor was considered with pleural effusion combined with cell mass immunohistochemistry. Gene detection: E279 K mutation emerges in BCR-ABL1 fusion gene in ABL1 kinase region. Bone marrowexamination: CM L( acute period). Timely discovery of leukemia cells in hydrothorax has important value for the progress in clinical judgment of disease and the adjustment of treatment plan.
出处 《浙江医学教育》 2017年第2期62-63,共2页 Zhejiang Medical Education
关键词 慢性粒细胞白血病 发热 胸水 细胞块 免疫细胞化学 chronicmyelogenousleukemia fever hydrothorax cell block immunohistochemistry
  • 相关文献

参考文献3

二级参考文献38

  • 1干定云,陈燕.慢性粒细胞白血病分子靶向治疗的新进展[J].临床血液学杂志,2006,19(3):190-192. 被引量:20
  • 2Weisberg E,Manley PW,Cowan-Jacob SW,et al.Secondgeneration inhibitors of BCR-ABL for the treatment ofimatinib-resistant chronic myeloid leukaemia[J].Nat RevCancer,2007,7(5):345-356. 被引量:1
  • 3Kantarjian H,Talpaz M,O′Brien S,et al.Survival benefitwith imatinib mesylate therapy in patients with accele-rated-phase chronic myelogenous leukemia——compari-son with historic experience[J].Cancer,2005,103(10):2099-2108. 被引量:1
  • 4Hochhaus A,Kreil S,Corbin AS,et al.Molecular andchromosomal mechanisms of resistance to imatinib(STI571)therapy[J].Leukemia,2002,16(11):2190-2196. 被引量:1
  • 5Golemovic M,Verstovsek S,Giles F,et al.AMN107,anovel aminopyrimidine inhibitor of Bcr-Abl,has in vitroactivity against imatinib-resistant chronic myeloid leuke-mia[J].Clin Cancer Res,2005,11(13):4941-4947. 被引量:1
  • 6O′Hare T,Walters DK,Stoffregen EP,et al.In vitro ac-tivity of Bcr-Abl inhibitors AMN107and BMS-354825a-gainst clinically relevant imatinib-resistant Abl kinase do-main mutants[J].Cancer Res,2005,65(11):4500-4505. 被引量:1
  • 7Weisberg E,Manley PW,Breitenstein W,et al.Characte-rization of AMN107,a selective inhibitor of native andmutant Bcr-Abl[J].Cancer Cell,2005,7(2):129-141. 被引量:1
  • 8Koren-Michowitz M,le Coutre P,Duyster J,et al.Activi-ty and tolerability of nilotinib:a retrospective multicenteranalysis of chronic myeloid leukemia patients who areimatinib resistant or intolerant[J].Cancer,2010,116(19):4564-4572. 被引量:1
  • 9Kantarjian H,Giles F,Wunderle L,et al.Nilotinib in ima-tinib-resistant CML and Philadelphia chromosome-posi-tive ALL[J].N Engl J Med,2006,354(24):2542-2551. 被引量:1
  • 10Kantarjian HM,Giles F,Gattermann N,et al.Nilotinib(formerly AMN107),a highly selective BCR-ABL tyro-sine kinase inhibitor,is effective in patients with Philadel-phia chromosome-positive chronic myelogenous leukemiain chronic phase following imatinib resistance and intole-rance[J].Blood,2007,110(10):3540-3546. 被引量:1

共引文献24

同被引文献16

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部